Jefferies Financial Group’s Denali Therapeutics DNLI Stock Holding History

Jefferies Financial Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$885K	Hold	34,425	–	–	0.01%	1023
2026 Q1	$661K	Buy	+34,425	New	+$685K	﹤0.01%	1088
2024 Q2	–	Sell	-69,314	Closed	-$1.42M	–	1516
2024 Q1	$1.42M	Sell	69,314 -96,013	-58%	-$1.8M	0.01%	697
2023 Q4	$3.55M	Buy	165,327 +152,527	+1,192%	+$3.02M	0.02%	508
2023 Q3	$264K	Buy	+12,800	New	+$325K	﹤0.01%	1264
2023 Q2	–	Sell	-263,123	Closed	-$6.06M	–	1752
2023 Q1	$6.06M	Buy	+263,123	New	+$7.24M	0.05%	318

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jefferies Financial Group's DNLI Position: Q2 2026 in Review

Jefferies Financial Group held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 34,425 shares worth $885K. The position accounts for 0.01% of the portfolio, ranked #1023.

Jefferies Financial Group first reported a position in DNLI in Q1 2023 and has held it in 6 quarters since. The position peaked at $6.06M in Q1 2023. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Jefferies Financial Group held 34,425 shares of Denali Therapeutics worth $885K as of Q2 2026.
Jefferies Financial Group left its Denali Therapeutics share count unchanged in Q2 2026.
Denali Therapeutics made up 0.01% of Jefferies Financial Group's portfolio in Q2 2026, its #1023 holding.
Jefferies Financial Group first reported a position in Denali Therapeutics in Q1 2023 and has held it in 6 quarters since.
Jefferies Financial Group's Denali Therapeutics position peaked at $6.06M in Q1 2023.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.